Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of afoxolaner and milbemycin oxime chewable tablets in China. Welcome to wholesale bulk high quality afoxolaner and milbemycin oxime chewable tablets for sale here from our factory. Good service and reasonable price are available.
Afoxolaner and milbemycin oxime chewable tablets, sold under the brand name NexGard Spectra®, are broad‑spectrum anthelmintic products developed specifically for dogs. The formulation provides comprehensive internal and external parasite control through a dual mechanism of action. Afoxolaner, an isoxazoline insecticide and acaricide, acts by inhibiting gamma‑aminobutyric acid (GABA)‑gated chloride channels in target parasites. This inhibition disrupts normal nerve signal transmission, leading to hyperexcitation, paralysis, and eventual death of external parasites including fleas and ixodid. This drug is a macrolide anthelmintic, exerts its effect by activating glutamate‑gated chloride channels, which induces hyperpolarization of neuromuscular cells in susceptible parasites. This hyperpolarization results in paralysis and death of internal parasites such as heartworms and gastrointestinal nematodes. Together, the two active ingredients deliver broad‑spectrum, dual‑action protection against a wide range of internal and external parasites in dogs.
Our product
The pharmaceuticals is in the form of light red to reddish brown tablets, with specifcations covering the needs of dogs weighing 2-50kg, including five combintions: 9.375mg+1.875mg to 150mg+30mg. Pharmacokinetic studies have shown that Aflana reaches its peak 2-4 hours after oral supervise and has a half-life of approximately 2 weeks; Milbeixime A3/A4 components reach their peak within 1-2 hours, with half lives of 1.6 and 3.3 days, respectively, ensuring long-lasting protection.
Basic information of drugs
Common name:
Aflanamir Beixime Chewable Tablets
01
Product Name:
NexGard Spectra ®), Fuweien ® (FRONTPRO)
02
English name:
Afoxolaner and Milbemycin Oxime Chewable Tablets
03
Manufacturer:
Boehringer Ingelheim Animal Health Co., Ltd., Toulouse, France
04
Dosage form and characteristics:
Light red to reddish-brown round (low spec) or square (high spec) tablets, palatable for dogs.
05
Specfication system:
Ultra trustworthy series:
Afurana 9.375mg+Milberoxime 1.875mg
Aflana 18.75mg+Milberoxime 3.75mg
Aflana 37.50mg+Milberoxime 7.50mg
Afurana 75.00mg+Milberoxime 15.00mg
Afurana 150.00mg+Milberoxime 30.00mg
Fuweien ® Series:
Afurana 11.3mg
Afurana 28.3mg
Afurana 68mg
Afurana 136mg
Import registration information:
According to the announcement of the Ministry of Agriculture and Rural Affairs, the drug will be re registered in 2023, and the registration certificate number for imported veterinary drugs includes (2018) Foreign Veterinary Drug Certificate No. 19-23, valid until January 16, 2028.
Afoxolaner and Milbemycin Oxime Chewable Tablets are a broad-spectrum deworming pharmaceuticals designed specifically for dogs, marketed as NexGard Spectra ®. This drug achieves internal and external co drive through a dual mechanim of action, covering the prevention and treatment of external parasites such as fleas, ixodid, mites, as well as internal parasites such as hertworms and gastroitestinal nemtodes. Its uses can be systematically summarized into the following core areas:
Ear mite infection:
Although not explicitly listed as an indication, milberoxime has a killing effect on the larvae and adults of Otodectes cynotis. In clinical practice, veterinarians may use it as part of comprehensive treatment for ear mites (such as in combintion with topical pharmaceuticals), especially for cases of systemic mite infection or recurrence.
Prevention and treatment of ectoparasites in cats (use beyond instructions):
Although the drug is labeled as for dogs, Aflana is equally effective against cat fleas (cat flea). In multi pet households, if a cat accidentally eats dog chew tablets or after a veterinary assessment of the risk, caution may be exercised when using them for flea control in cats (strict dosage adjustment is necessary to avoid excessive poisoning from Mirbesime).
2. Preventive use in high-risk environments for parasitic infections
Stray animal rescue station:
In shelters for stray animals with high incidence of fleas and ixodid, this drug can be used as a group prevention plan to reduce the risk of parasite transmission, especially suitable for scenarios where it is difficult to externally deworming each individual.
Wildlife conservation:
The prevention and control of parasitic infections in endangered canine species such as foxes and jackals require careful use after veterinary evaluation, which may involve dosage adjustments beyond the instructions or combintion therapy.
Combined with P-glycoprotein inhibitors:
Milberoxime is a substrate of P-glycoprotein (P-gp), and when used in combintion with P-gp inhibitors such as ketoconazole, it may enhance its blood drug concentration and prolong its efficacy. This characteristic may be used to treat drug-resistant nemtode infections, but strict monitoring of toxicity reactions is required.
Cases of failed replacement therapy:
Milberoxime may be an alternative for nemtode or mite infections resistant to conventional insecticides such as ivermectin, but its effectiveness needs to be validated through drug sensitivity testing.
4. Adjuvant therapy for non parasitic diseases (theoretical possibility)
Immune regulatory effect:
Parasitic infections may trigger an overreaction of the dog's immune system, leading to skin inflammation or allergies. The drug may indirectly alleviate related symptoms by clearing parasites, but there is no direct evidence to support its immune regulatory function.
Postoperative infection prevention:
Postoperative dogs are susceptible to parasitic infections due to weakened immunity. This pharmaceuticals can be used as a preventive measure, but the type of surgery and the risk of drug interaction need to be evaluated.
Super trustworthy series: Select specfications based on dog weight and take orally once a month.
2-4kg: 9.375mg Aflana+1.875mg Milberoxime
4.1-10kg: 18.75mg Aflana+3.75mg Milberoxime
10.1-25kg: 37.5mg Aflana+7.5mg Milbeixime
25.1-50kg: 75mg Aflana+15mg Milberoxime
＞ 50kg: Use high specfication tablets in combintion to ensure the dosage is within the range of 2.5-6.9mg/kg.
Afoxolaner and milbemycin oxime chewable tablets series: Dose calculated based on the content of Afurana, ranging from 2.7-7.0mg/kg, once a month.
Collie: Due to MDR1 gene defects, drug accumulation may occur, and dosage adjustment or avoidance of use should be based on veterinary advice.
Pregnant/lactating dogs: Safety data is limited and should be used with caution under veterinary guidance.
Puppies: Dogs under 8 weeks of age or weighing less than 2kg are prohibited.
It can be fed directly or mixed into food to ensure complete feeding for dogs.
The remaining pills should be returned to their original packaging to avoid contact with children.
Wash hands after use to prevent gastroitestinal disorders caused by accidental ingestion.
Pharmacological mechanim of action
1. Afoxolane
'lt is awesome to work with Creative. amazingy organized,easy to communicate with. responsive with next iterations,and beautiful work.
Category:
Isoxazoline insecticides/acaricides
Target:
Ligand gated chloride ion channel (gamma aminobutyric acid, GABA receptor)
Mechanim:
Inhibiting GABA-gated channels blocks chloride ion transmission, causing insect neuronal hyperexcitation and death.
Specificity:
The affinity for GABA receptors in arthropods (fleas, ixodid, mites) is much higher than in mammals, ensuring safety for dogs.
2. Milbemycin Oxime
Category
Macrolide Antiparasitic Drugs
Composition
Milberoxime A3 (20%) and A4 (80%)
Target
Chloride ion channels controlled by glutamate in invertebrate nerve and muscle cells
Mechanim
After binding with chloride ion channels, it enhances membrane permeability, triggers cell hyperpolarization, and leads to parasite paralysis and death.
Safety advantage
The blood-brain barrier of mammals has extremely low permeability to milberoxime, and the distribution of GABA receptors in the central nervous system is limited, so it has no significant effect on nerve conduction in dogs.
Pharmacokinetic characteristics
1. Afurana
Absorption:
After oral supervise in dogs, the absorption is complete, with an absolute bioavailability of 88%, a peak time (Tmax) of 2-4 hours, and a peak concentration (Cmax) of 1822 ± 165ng/ml.
Distribution:
The tissue distribution volume is 2.6 ± 0.6L/kg, the plasma clearance rate is 5.0 ± 1.2ml/h/kg, and the plasma half-life is about 2 weeks.
Metabolic excretion:
Mainly through liver metabolism, excreted through feces and urine.
2. Milberoxime
Absorption:
After oral supervise, the absorption is rapid, and the absolute bioavailability of Milbeixime A3 and A4 is 81% and 65%, respectively, with a peak time of 1-2 hours.
Distribution:
The tissue distribution volumes were 2.7 ± 0.4L/kg (A3) and 2.6 ± 0.6L/kg (A4), respectively, with low plasma clearance rates (A3: 75 ± 22ml/h/kg, A4: 41 ± 12ml/h/kg).
Half life:
A3 is 1.6 ± 0.4 days, A4 is 3.3 ± 1.4 days, and the long-acting effect ensures the effectiveness of monthly supervise.
3. Drug interactions
Milbeixime is a substrate of P-glycoprotein (P-gp), and its combintion with P-gp substrates such as digoxin and doxorubicin, or macrolide drugs, may enhance toxicity. Therefore, combintion therapy should be avoided.
Research and Development Background and Market Position
Afoxolaner and milbemycin oxime chewable tablets were developed by Boehringer Ingelheim, combining Aflanamir's broad-spectrum insecticidal activity with Milbesylate's antibody parasite properties to form an innovative formula for both internal and external driving. In 2018, it obtained import registration from the Ministry of Agriculture and Rural Affairs of China for the first time, and completed re registration in 2023, becoming a benchmark product in the domestic dog insecticide market.
Efficiency: A single supervise can simultaneously solve the problems of fleas, ixodid, hertworms, and gastroitestinal nemtodes.
Safety: Pharmacokinetic optimization ensures low toxicity and wide applicability to breeds other than Collie Shepherd.
Convenience: Oral once a month, with a palatability design to improve dog compliance.
In the global market for deworming drugs for dogs, the ultra reliable series holds over 30% of the market share, especially becoming the preferred preventive drug in areas with high incidence of hertworm disease. The domestic market is widely covered through veterinary channels and e-commerce platforms, with annual sales exceeding 500 million yuan.
Hot Tags: afoxolaner and milbemycin oxime chewable tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale